Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
As far as the cellular targets are concerned, our scanning electron images show morphological alterations of the bacterial cell wall after administration of a sub-lethal light dose
Research use Amylin receptor pathway studies Satiety and metabolic-response models Combination research with GLP-1 pathway compounds Best grouped with GLP-1 and incretin products in the diabetes and weight-loss hubs
Natural production declines with age, stress, pollutant exposure and lifestyle recent research suggests oral supplementation at 2501,000mg/day can help raise plasma and intracellular GSH levels
"Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs"
US$ 21.85
US$ 28.16
US$ 22.51
US$ 22.60
US$ 28.96
